|Description||PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human MDA-MB-468 cells.|
|Synonyms||PI-1840; PI 1840; PI1840|
Epoxomicin is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. It inhibits pr...
PSI is a drug that blocks the action of proteasomes, protein complexes that degrade unneeded and damaged proteins. It causes dopaminergic cell death in vitro an...
Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
PD 150606 is a selective, cell-permeable inhibitor of calpains (Ki = 0.21 μM for μ-calpain (calpain-1) and 0.37 μM for m-calpain (calpain-2)). It targets the ca...
PD 151746 is a selective, cell-permeable calpain inhibitor with Ki of 0.26 μM for μ-Calpain, about 20-fold selectivity over m-calpain.
RA190, a bis-benzylidine piperidon, is a novel potent and selective inhibitor of proteasome ubiquitin receptor RPN13/ADRM1. RA190 stabilized targets of human pa...
The citrate salt form of Ixazomib which is a proteasome inhibitor. It is considered a rollover Phase II trial against multiple myeloma, amyloidosis and lymphoma...
PI-1840 potently inhibits proteasomal CT-L activity with IC50 of 0.37 μM in intact human MDA-MB-468 cancer cells, and inhibits proliferation/survival of human M...